Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
About this item
Full title
Author / Creator
METEOR Investigators , Choueiri, Toni K , Escudier, Bernard , Powles, Thomas , Mainwaring, Paul N , Rini, Brian I , Donskov, Frede , Hammers, Hans , Hutson, Thomas E , Lee, Jae-Lyun , Peltola, Katriina , Roth, Bruce J , Bjarnason, Georg A , Géczi, Lajos , Keam, Bhumsuk , Maroto, Pablo , Heng, Daniel Y.C , Schmidinger, Manuela , Kantoff, Philip W , Borgman-Hagey, Anne , Hessel, Colin , Scheffold, Christian , Schwab, Gisela M , Tannir, Nizar M and Motzer, Robert J
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
In a phase 3 clinical trial involving previously treated patients with advanced renal-cell carcinoma, progression-free survival was significantly longer with the VEGF receptor inhibitor cabozantinib than with everolimus (7.4 months vs. 3.8 months).
Renal-cell carcinoma is the most common form of kidney cancer, with more than 330,000 cases diagno...
Alternative Titles
Full title
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Authors, Artists and Contributors
Author / Creator
Choueiri, Toni K
Escudier, Bernard
Powles, Thomas
Mainwaring, Paul N
Rini, Brian I
Donskov, Frede
Hammers, Hans
Hutson, Thomas E
Lee, Jae-Lyun
Peltola, Katriina
Roth, Bruce J
Bjarnason, Georg A
Géczi, Lajos
Keam, Bhumsuk
Maroto, Pablo
Heng, Daniel Y.C
Schmidinger, Manuela
Kantoff, Philip W
Borgman-Hagey, Anne
Hessel, Colin
Scheffold, Christian
Schwab, Gisela M
Tannir, Nizar M
Motzer, Robert J
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5024539
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5024539
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1510016
